Dramatically changing rates and reasons for hospitalization in multiple sclerosis

Neurology

Volumn 83, Issue 10, 2014, Pages 929-937

  Marrie, Ruth Ann ^a   Elliott, Lawrence ^a   Marriott, James ^a   Cossoy, Michael ^a   Blanchard, James ^a   Tennakoon, Aruni ^a   Yu, Nancy ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Manitoba Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL PNEUMONIA; CANADA; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DECUBITUS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFLUENZA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEOPLASM; POPULATION RESEARCH; PRIORITY JOURNAL; SENESCENCE; SEX DIFFERENCE; SOCIAL STATUS; URINARY TRACT INFECTION; ADULT; AGE; COHORT ANALYSIS; COMORBIDITY; FEMALE; MALE; MIDDLE AGED; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; AGE FACTORS; COHORT STUDIES; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MANITOBA; MIDDLE AGED; MULTIPLE SCLEROSIS; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 84922233046     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000753     Document Type: Article

References (40)

1. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology 2005;65:1066-1070.
2. Kingwell E, Leung AL, Roger E, Duquette P, Rieckmann P, Tremlett H. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci 2010;292:57-62.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661.
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
5. Marrie RA, Yu N, Wei Y, Elliott L, Blanchard J. High rates of physician services utilization at least five years before multiple sclerosis diagnosis. Mult Scler J 2013;19: 1113-1119.
6. Lad S, Chapman C, Vaninetti M, Steinman L, Green A, Boakye M. Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology 2010;35:93-99.
7. Stolp-Smith KA, Atkinson EJ, Campion ME, O'Brien PC, Rodriguez M. Health care utilization in multiple sclerosis. Neurology 1998;50:1594-1600.
8. Pope GC, Urato CJ, Kulas ED, Kronick R, Gilmer T. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002;58: 37-43.
9. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-926.
10. Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-712.
11. McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple sclerosis in the UK: service use, costs, quality of life and disability. PharmacoEconomics 2008;26:847-860.
12. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52.
13. Evans C, Kingwell E, Zhu F, Oger J, Zhao Y, Tremlett H. Hospital admissions and MS: temporal trends and patient characteristics. Am J Manag Care 2012;18:735-742.
14. Canadian Institute for Health Information. Highlights of 2008-2009 Inpatient Hospitalizations and Emergency Department Visits. Ottawa, ON: CIHI; 2010.
15. Manitoba Bureau of Statistics. Manitoba's Population Trends Past, Present and Future. Winnipeg, MB: Manitoba Bureau of Statistics; 2008.
16. Health Information Management Branch. Population Report. Winnipeg, MB: Manitoba Health and Healthy Living; 2008.
17. Marrie RA, Yu N, Blanchard JF, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010;74:465-471.
18. Jacobs P, Noseworthy TW. National estimates of intensive care utilization and costs: Canada and the United States. Crit Care Med 1990;18:1282-1286.
19. Sirio CA, Tajimi K, Taenaka N, Ujike Y, Okamoto K, Katsuya H. A cross-cultural comparison of critical care delivery: Japan and the United States. Chest 2002;121: 539-548.
20. Wunsch H, Angus DC, Harrison DA, et al. Variation in critical care services across North America and Western Europe. Crit Care Med 2008;36:2787-2793.
21. Halpern NA, Bettes L, Greenstein R. Federal and nationwide intensive care units and healthcare costs: 1986-1992. Crit Care Med 1994;22:2001-2007.
22. Longobardi T, Bernstein CN. Health care resource utilization in IBD. Clin Gastroenterol Hepatol 2006;4:731-743.
23. Booth GL, Hux JE. Relationship between avoidable hospitalizations for diabetes mellitus and income level. Arch Intern Med 2003;163:101-106.
24. Canadian Institute for Health Information. The Burden of Neurological Diseases, Disorders and Injuries in Canada. Ottawa, Canada: Canadian Institute for Health Information; 2007.
25. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999;341:1359-1367.
26. Li X, Hemminki K, Sundquist K. Regional, socioeconomic and occupational groups and risk of hospital admission for multiple sclerosis: a cohort study in Sweden. Mult Scler 2008;14:522-529.
27. Tu JV, Nardi L, Fang J, et al. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994-2004. Can Med Assoc J 2009;180:E118-E125.
28. Roos N, Stranc L, Peterson S, Mitchell L, Bogdanovic B, Shapiro E. A Look at Home Care in Manitoba. Winnipeg, MB: Manitoba Centre for Health Policy and Evaluation; 2001.
29. Evans C, Beland S, Kulaga S, et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 2013;40:195-210.
30. Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol 2013;20:1153-1160.
31. Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology 2006; 26:102-107.
32. Kingwell E, Bajdik C, Phillips N, et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 2012;135:2973-2979.
33. Marrie RA, Yu BN, Leung S, et al. Prevalence and incidence of ischemic heart disease in multiple sclerosis: a population-based validation study. Mult Scler Relat Disord 2013;2:355-361.
34. Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Alderman MH. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology 2008;30:234-238.
35. Fleming ST, Blake RL Jr. Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol 1994;47:1127-1132.
36. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-710.
37. Mustard CA, Derksen S, Berthelot JM, Wolfson M. Assessing ecologic proxies for household income: a comparison of household and neighbourhood level income measures in the study of population health status. Health & Place 1999;5:157-171.
38. Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 2010;35:267-274.
39. Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler J 2013;19:1336-1340.
40. Putzki N, Pfriem A, Limmroth V, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol 2009;16:262-267.